ArticleClinical and translational allergy2015
The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey.
Article in Clinical and translational allergy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial.Allergy and asthma proceedings · 2018Trial
- Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial.Brazilian journal of otorhinolaryngologyTrial
- Global Research Trends in Chronic Care for Comorbid Allergic Diseases: A Web of Science Bibliometric Review (1999-2024).Current allergy and asthma reports · 2025Review
- Disease burden in children with moderate to severe perennial allergic rhinitis and concomitant asthma in Canada, Denmark, and the United Kingdom.The journal of allergy and clinical immunology. Global · 2025Article
- Evaluating efficacy and safety of auricular acupressure in treating allergic rhinitis: A randomized controlled trial.Integrative medicine research · 2025Article
- ARIA-Italy managing allergic rhinitis and asthma in a changing world: The role of the Pharmacist.The World Allergy Organization journal · 2025Review
- Quality of life and healthcare costs of patients with allergic respiratory diseases: a cross-sectional study.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Allergic rhinitis facts from an Irish pediatric population.World journal of otorhinolaryngology - head and neck surgery · 2023Article
- A double-blind, placebo-controlled trial of the efficacy and safety of two doses of azelastine hydrochloride in perennial allergic rhinitis.Frontiers in allergy · 2023Article
- 25-year retrospective longitudinal study on seasonal allergic rhinitis associations with air temperature in general practice.NPJ primary care respiratory medicine · 2022Article
- The relative proportion of comorbidities among rhinitis and rhinosinusitis patients and their impact on visit burden.Clinical and translational allergy · 2022Article
- A fifteen-year review of skin allergy testing in Irish patients with symptomatic rhinitis.World journal of otorhinolaryngology - head and neck surgery · 2021Review
- Combinations of self-reported rhinitis, conjunctivitis, and asthma predicts IgE sensitization in more than 25,000 Danes.Clinical and translational allergy · 2021Article
- Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care.The World Allergy Organization journal · 2020Article
- Medication Adherence in a Community Population with Uncontrolled Asthma.Pharmacy (Basel, Switzerland) · 2020Article
- Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.The Journal of allergy and clinical immunology · 2020Review
- Qualitative Exploration of Pharmacists' Feedback Following the Implementation of an "Allergic Rhinitis Clinical Management Pathway (AR-CMaP)" in Australian Community Pharmacies.Pharmacy (Basel, Switzerland) · 2020Article
- ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-Türkiye.Turkish thoracic journal · 2020Review
- Grand Challenges in Rhinology.Frontiers in allergy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe affliction of allergic rhinitis (AR) has been trivialised in the past. Recent initiatives by the European Academy of Allergy & Clinical Immunology and by the EU parliament seek to rectify that situation. The aim of this study was to provide a comprehensive picture of the burden and unmet need of AR patients.
methodsThis was a cross-sectional, online, questionnaire-based study (June-July 2011) including symptomatic seasonal AR (SAR) patients (≥18 years) from a panel. SAR episode pattern, severity, medication/co-medication usage, residual symptoms on treatment, number of healthcare visits, absenteeism and presenteeism were collected.
resultsOne thousand patients were recruited (mild: n = 254; moderate/severe: n = 746). Patients with moderate/severe disease had significantly more symptomatic episodes/year (8.0 vs 6.0/year; p = 0.025) with longer episode-duration (12.5 vs 9.8 days; p = 0.0041) and more commonly used ≥2 AR therapies (70.5 vs 56.1 %; OR 1.87; p = 0.0001), looking for better and faster nasal and ocular symptom relief. The reported symptom burden was high irrespective of treatment, and significantly (p < 0.0001) higher in the moderate/severe group. Patients with moderate/severe AR were more likely to visit their GP (1.61 vs 1.19 times/year; OR: 1.49; p = 0.0061); due to dissatisfaction with therapy in 35.4 % of cases. Patients reported SAR-related absenteeism from work on 4.1 days/year (total cost to UK: £1.25 billion/year) and noted presenteeism for a mean of 37.7 days/year (vs 21.0 days/year; OR 1.71; p = 0.0048). Asthma co-morbid patients reported the need to increase their reliever- (1 in 2 patients) and controller-medication (1 in 5 patients) if they did not take their rhinitis medication.
conclusionsThis study differentiated between patients with mild and moderate/severe AR, demonstrating a burden of poorly controlled symptoms and high co-medication use. The deficiency in obtaining symptom control with what are currently considered firstline treatments suggests the need for a novel therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.